{"denoms":[{"counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"120"},{"groupId":"BG004","value":"171"}],"units":"Participants"}],"groups":[{"description":"Group A: Open label AZD4205 at 150 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"BG000","title":"AZD4205 Group A"},{"description":"Group B: Open label AZD4205 at 250 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"BG001","title":"AZD4205 Group B"},{"description":"Group C: Open label AZD4205 at 150 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"BG002","title":"AZD4205 Group C"},{"description":"Group D: Open label AZD4205 at the 150 mg (RP2D), once daily (Phase 2)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"BG003","title":"AZD4205 Group D"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"33","upperLimit":"78","value":"62.5"},{"groupId":"BG001","lowerLimit":"29","upperLimit":"79","value":"61.5"},{"groupId":"BG002","lowerLimit":"39","upperLimit":"74","value":"55.0"},{"groupId":"BG003","lowerLimit":"20","upperLimit":"79","value":"58.0"},{"groupId":"BG004","lowerLimit":"20","upperLimit":"79","value":"58.0"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"44"},{"groupId":"BG004","value":"61"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"76"},{"groupId":"BG004","value":"110"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"100"},{"groupId":"BG004","value":"151"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"4"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"14"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"Safety Analysis Set (all patients treated with at least one dose of AZD4205)"}